The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
History shows that the market's biggest winners typically have an 80 or higher RS Rating as they begin their biggest runs.
Looking For Winning Stocks? Try This Simple Routine
Is Stryker Stock A Buy?
Stryker stock has risen more than 5% past a 306.93 entry in a first-stage consolidation, meaning it's extended and now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings growth dropped last quarter from 16% to 15%, but the top line rose from 10% to 12%.
Stryker stock holds the No. 3 rank among its peers in the Medical-Products industry group. DexCom and Boston Scientific are also among the group's highest-rated stocks.
